Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Patient Satisfaction 2Urologic Neoplasms 1Thyroid Cancer, Papillary 1Sarcoma, Ewing 1Sarcoma 1Radiation Injuries 1Patient Preference 1Patient Acceptance of Health Care 1Osteosarcoma 1Osteitis Deformans 1Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Cyclophosphamide 25Temozolomide 22Vincristine 18Irinotecan 18Doxorubicin 13Topotecan 10Melphalan 10Etoposide 10Ifosfamide 8Busulfan 8cabozantinib 7Magnetic Resonance Spectroscopy 7Granulocyte Colony-Stimulating Factor 7Filgrastim 6regorafenib 5fludarabine 5X-Rays 5Specimen Handling 5Sirolimus 5Radiotherapy 5Gemcitabine 5Drug Therapy 5pegfilgrastim 4palbociclib 4liposomal doxorubicin 4irinotecan sucrosofate 4ganitumab 4fludarabine phosphate 4Trabectedin 4Phantoms, Imaging 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × delta 24-sterol reductase × Clear all
NCT01882231 2017-05-08

Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
6 enrolled
Sarcoma

Bone Neoplasms, Osteitis Deformans, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡